GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acino Holding AG (FRA:S3H) » Definitions » EBIT

Acino Holding AG (FRA:S3H) EBIT : €-15.0 Mil (TTM As of Dec. 2013)


View and export this data going back to . Start your Free Trial

What is Acino Holding AG EBIT?

Acino Holding AG's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2013 was €-15.0 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2013 was €-15.0 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Acino Holding AG's annualized ROC % for the quarter that ended in Dec. 2013 was -2.63%. Acino Holding AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2013 was -6.77%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Acino Holding AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2013 was -4.79%.

Acino Holding AG EBIT Historical Data

The historical data trend for Acino Holding AG's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acino Holding AG EBIT Chart

Acino Holding AG Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 44.51 -2.66 6.68 6.48 -14.98

Acino Holding AG Semi-Annual Data
Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 44.51 -2.66 6.68 6.48 -14.98

Competitive Comparison of Acino Holding AG's EBIT

For the Drug Manufacturers - General subindustry, Acino Holding AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acino Holding AG's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acino Holding AG's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Acino Holding AG's EV-to-EBIT falls into.


Acino Holding AG EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT for the trailing twelve months (TTM) ended in Dec. 2013 was €-15.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acino Holding AG  (FRA:S3H) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Acino Holding AG's annualized ROC % for the quarter that ended in Dec. 2013 is calculated as:

ROC % (Q: Dec. 2013 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2012 ) + Invested Capital (Q: Dec. 2013 ))/ count )
=-14.975 * ( 1 - 22.38% )/( (455.914 + 427.663)/ 2 )
=-11.623595/441.7885
=-2.63 %

where

Invested Capital(Q: Dec. 2012 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=505.815 - 32.185 - ( 17.716 - max(0, 84.556 - 149.049+17.716))
=455.914

Invested Capital(Q: Dec. 2013 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=458.051 - 20.362 - ( 10.026 - max(0, 63.917 - 127.678+10.026))
=427.663

Note: The Operating Income data used here is one times the annual (Dec. 2013) data.

2. Joel Greenblatt's definition of Return on Capital:

Acino Holding AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2013 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2013 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2012  Q: Dec. 2013
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-14.975/( ( (159.365 + max(65.328, 0)) + (151.668 + max(66.042, 0)) )/ 2 )
=-14.975/( ( 224.693 + 217.71 )/ 2 )
=-14.975/221.2015
=-6.77 %

where Working Capital is:

Working Capital(Q: Dec. 2012 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(57.938 + 61.899 + 11.496) - (32.185 + 0 + 33.82)
=65.328

Working Capital(Q: Dec. 2013 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(53.689 + 56.415 + 7.548) - (20.362 + 0 + 31.248)
=66.042

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (Dec. 2013) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Acino Holding AG's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2013 )
=-14.975/312.559
=-4.79 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acino Holding AG EBIT Related Terms

Thank you for viewing the detailed overview of Acino Holding AG's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Acino Holding AG (FRA:S3H) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acino Holding AG (FRA:S3H) » Definitions » EBIT
Comparable Companies
SZSE:002198 IST:ECILC SZSE:000411 SZSE:000605 SZSE:000952 XKRX:003090 XKRX:058820 CAS:SOT SHSE:600613 SZSE:000705 SHSE:600666 ASX:MYX TSE:4550 BSE:SCD SHSE:600421 XKRX:039200 BSP:PNVL3 SHSE:600614 SHSE:600671 SZSE:300006
Traded in Other Exchanges
N/A
Address
Website
http://www.acino-pharma.com
Acino Holding AG is a Switzerland-based company engaged in the pharmaceutical industry. The Company develops, manufactures, and markets pharmaceuticals in novel drug delivery forms internationally. It is divided into four segments Business to Consumer (BtC); Business to Business (BtB); Technology marketing (TM); and Production (Prod). The BtC segment comprises all direct marketing activities. Under the company's "Acino Switzerland" brand and, with the promise of Swiss quality, the company sells its products in emerging markets around the globe. This reporting segment includes the business purchased from Mepha/Cephalon in the Middle East, Africa, Latin America and Asia. The BtB segment comprises Acino's business with its internally developed products, for which the company also owns the intellectual property rights. Acino develops and produces high-quality medicines with proven active ingredients and modern drug delivery systems and grants licenses for them to leading pharmaceutical and generic pharmaceutical companies worldwide. The technology marketing segment comprises a broad spectrum of fully integrated contract services, including procurement, contract development, production and packaging for companies in the life sciences industry. On behalf of these customers, Acino develops a comprehensive product pipeline on the basis of its special technological know-how. This includes both new types of medicines as well as projects with innovative drug delivery systems for established active ingredients. The production segment is responsible for the manufacturing of products and the supplying of the other three segments, and generates turnover through the reimbursement of its services. The manufacturing costs of products are credited to the production segment at standard prices along with remuneration in the form of a mark-up for materials and production costs.

Acino Holding AG (FRA:S3H) Headlines

No Headlines